Level Bio AB
NNGM:LEVBIO0.23
SEK
0.00
(0.00%)
ISIN
SE0000885501
Return %
Stock
S&P 500
1Y
-39.36
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Joakim Grånemo
- Full Time Employees
- 10
- Sector
- Distribution services
- Industry
- Medical distributors
- Address
- Nacka Sweden
- IPO Date
- Sep 15, 2006
- Website
- alphahelix.com
- Similar Companies
- Business
- Level Bio AB (publ) is a Sweden-based life sciences and biotechnology company that develops, manufactures, and commercializes diagnostic technologies, bioanalytical tools, and specialized biomedical solutions for clinical healthcare and research applications. The company operates across key segments within diagnostics and laboratory technology, delivering products and solutions designed to enhance disease detection, biological sample analysis, and clinical workflows. The company's core product and service portfolio comprises in vitro diagnostic (IVD) test kits and assay panels for clinical diagnostics and biomarker detection; proprietary sample preparation and bioanalytical testing systems; specialized laboratory consumables, reagents, and biochemical assay kits; diagnostic instruments and point-of-care testing devices; and specialized contract analysis, assay development, and laboratory support services tailored for healthcare providers, research facilities, and biopharmaceutical developers. Level Bio AB serves clinical pathology laboratories, hospitals, academic and governmental research institutions, contract research organizations (CROs), and biotechnology and pharmaceutical companies across the Nordic region, greater Europe, and international markets. Headquartered in Stockholm, Sweden, Level Bio AB was established to address critical diagnostic and biomedical testing needs and lists its shares on the Nordic Growth Market (NGM) under the ticker symbol LEVBIO. In recent developments, Level Bio AB has undertaken corporate restructuring and strategic reorganization initiatives to optimize its operating model and focus resources on commercializing high-margin diagnostic platforms. The company has secured growth capital through equity financing rounds to support product development pipelines, regulatory compliance, and market expansion. In addition, Level Bio AB has expanded its commercial reach through new distribution agreements and strategic partnerships across key European territories, while broadening its product offerings through the launch of next-generation assay kits and enhanced diagnostic testing capabilities aimed at precision medicine and decentralized laboratory environments.